Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX301 Phase 1/2 in Advanced Solid Tumors and Lymphoma
CTR20221234Phase 2Terminated
- Sponsor
- Fosun Pharma
- Start
- May 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of hlx301 in Nonhematologic neoplasms, lymphoma, non-small cell lung cancer (NSCLC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fosun Pharma. Started May 2022; status: terminated.
02
Drugs
hlx301
03
Conditions
Nonhematologic neoplasmslymphomanon-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20221234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221234.